# A Study of the Efficacy and Safety of CORLUX in the Treatment of Endogenous Cushing's Syndrome

> **NCT00569582** · PHASE3 · COMPLETED · sponsor: **Corcept Therapeutics** · enrollment: 50 (actual)

## Conditions studied

- Cushing's Syndrome

## Interventions

- **DRUG:** mifepristone

## Key facts

- **NCT ID:** NCT00569582
- **Lead sponsor:** Corcept Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-12
- **Primary completion:** 2011-01
- **Final completion:** —
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2013-08-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00569582

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00569582, "A Study of the Efficacy and Safety of CORLUX in the Treatment of Endogenous Cushing's Syndrome". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00569582. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*